Destiny Pharma PLC Directorate Change (2390V)
December 02 2019 - 1:01AM
UK Regulatory
TIDMDEST
RNS Number : 2390V
Destiny Pharma PLC
02 December 2019
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Directorate change
Destiny Pharma appoints Dr Debra Barker as Non-Executive
Director
Experienced pharmaceutical executive and medical director with
expertise in anti-infective drug development and in-licensing
Brighton, United Kingdom - 2 December 2019 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs that address clear
commercial opportunities and also address the global problem of
antimicrobial resistance (AMR), announces the appointment of Dr.
Debra Barker as an independent Non-Executive Director with effect
from 1 January 2020.
Dr. Barker is a seasoned pharmaceutical executive with more than
25 years' experience in the industry in both pharma and biotech
having worked at Novartis, Roche, GSK (then SmithKline Beecham) and
most recently at Polyphor as Chief Medical and Development Officer.
Dr. Barker is currently on the board of Hutman Diagnostics, a
molecular diagnostic company specialising in antimicrobial
resistance, and BerGenBio, an oncology company targeting
immune-evasive and therapy resistance cancers. At Novartis Dr.
Barker held several senior roles including development lead for the
acquisition of UK and US biotech anti-infective assets and the
in-licensing of GSK's late stage oncology portfolio. Dr. Barker was
also the medical lead for Swiss based anti-infective specialist
Polyphor's IPO on the SIX Swiss Exchange, raising 165m CHF in 2018,
the largest Swiss biotech IPO in 10 years.
Nick Rodgers, Chairman of Destiny Pharma, commented:
"We are delighted to announce Dr. Barker's appointment to the
Destiny board. Debra has significant experience of late stage drug
development, including anti-infectives and a long-standing interest
in microbiology and infection management in a clinical setting. Dr
Barker also has broader corporate experience of in-licencing and
portfolio development. These skills will be of immense value to
Destiny Pharma as we continue to develop the business and advance
our lead drug candidate, XF-73, which is currently in phase 2b
development for the prevention of post-surgical infections."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Debra Stephanie
Barker, aged 57, has been a director of the following companies
during the five years preceding the date of this announcement:
Current Past
Hutman Diagnostics AG Polyphor AG
Barker Biomedical Limited Polyphor UK Limited
BerGen Bio ASA
There is no further information to be disclosed pursuant to Rule
17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development and
commercialisation of novel medicines from its XF Platform that
represent a new approach to the treatment of infectious disease.
The company's lead programme is undergoing a Phase 2b clinical
trial and is targeting the prevention of post--surgical hospital
infections including MRSA. The XF drug candidates are being
developed for the prevention and treatment of life--threatening
infections caused by antibiotic--resistant bacteria, often referred
to as "superbugs". Tackling anti--microbial resistance has become a
global imperative recognised by the World Health Organisation (WHO)
and the United Nations, as well as the G7 and the G20 countries.
For further information, please visit
https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABCBDDSXGBGCB
(END) Dow Jones Newswires
December 02, 2019 02:01 ET (07:01 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2023 to Apr 2024